1. Introduction
===============

In the last few years, several multi-gene assays performed on tumor tissue from women with early breast cancer have been proposed to provide prognostic information and discriminate good *vs.* poor prognosis \[[@b1-ijms-14-09686]--[@b15-ijms-14-09686]\]. These assays might be useful to assist in making more informed treatment decisions regarding chemotherapy, according to the main international guidelines \[[@b16-ijms-14-09686],[@b17-ijms-14-09686]\].

The array gene expression analysis "Mammaprint®" identifies a 70 gene-signature indicative for poor prognosis in patients with lymph node-negative disease or with 1--3 positive nodes, predicting chemotherapy benefit in the "high risk" group, *vs.* no apparent benefit in the "low risk" group \[[@b3-ijms-14-09686]--[@b6-ijms-14-09686]\], in a non-randomized clinical setting. It needs fresh/frozen tissue of the primary breast tumors \[[@b2-ijms-14-09686],[@b3-ijms-14-09686]\]. The multigene assay "Oncotype DX^®^" evaluate gene expression analysis of 21 genes starting from paraffin-embedded tissue calculating a recurrence score to classify patients at low, intermediate, or high risk for recurrence. From two independent retrospective analyses from phase III clinical trial with adjuvant tamoxifen-alone control arms, the 21-gene recurrent score (RS) assay defines a group of patients with low scores who do not appear to benefit from chemotherapy, and a second group with very high scores who derive major benefit from chemotherapy, independently of age and tumor size \[[@b1-ijms-14-09686],[@b9-ijms-14-09686]--[@b11-ijms-14-09686]\].

Other studies using a supervised approach based on clinical outcome endpoint to tumor grade as a basis for gene findings have resulted in development of multiple commercial reference lab assays for prognostication (MapQuant Dx \[[@b14-ijms-14-09686]\], Theros Breast Cancer Index \[[@b15-ijms-14-09686]\]).

The above-mentioned multigene assays are expensive and validations have been made on patients selected by age and nodal or Estrogen Receptor status and or received adjuvant treatment.

Analyzing data from several array based gene expression wide analysis publicly available on NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>), we identified a subset of 20 mRNA differentially regulated in breast cancer. We activated a protocol evaluating these markers to create a new gene signature based on real time PCR from paraffin embedded tissue and on a "real life" breast cancer patient population. The enrolled cases were not selected for age, adjuvant treatment, nodal and estrogen receptor status.

2. Results and Discussion
=========================

Formalin-fixed and paraffin-embedded (FFPE) tissues represent one of the largest tissue sources, for which well-documented clinical follow-up is available, and therefore large-scale retrospective studies are possible \[[@b18-ijms-14-09686]\]. As described recently by Bussolati *et al.* \[[@b19-ijms-14-09686]\], in a near future the possibility of obtaining high-quality total RNA from archival tissues will guarantee a more powerful and robust gene expression analysis. In order to identify a small number of informative genes providing prognostic information for breast cancer, we evaluated *in silico* a set of published signatures and tested by gene expression array on the 408 breast cancer cases deposited in NCBI Gene Expression Omnibus. By several steps involving univariate analysis for the association with disease free survival (DFS), unsupervised hierarchical clustering algorithm, and multivariate Cox modelling selection, we found 20 highly related genes with DFS. These candidate genes were subsequently evaluated *in vitro* by RTqPCR analyzing a total of 261 cases representing the training (137 cases) and the validation (124 cases) datasets (see the workflow shown in [Figure 1](#f1-ijms-14-09686){ref-type="fig"}).

2.1. Gene Selection on the Published Datasets
---------------------------------------------

We used data deposited in NCBI Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>, GEO Series accession number GSE1456 and GSE3494), including 408 breast cancer cases. Files containing raw intensity data of Affymetrix HU133A and HU133B arrays of the two datasets (GSE1456 and GSE3494) were preprocessed using R/Bioconductor (GCRMA package, quantile normalization, median polish summarization). The two data sets were pre-processed together using the supercomputer Michelangelo (<http://www.litbio.org>). The candidate genes were selected from the above mentioned datasets as those included in 4 previously proposed signatures: the "70-gene signature" developed by van de Vijver *et al.* \[[@b3-ijms-14-09686]\] and van't Veer *et al.* \[[@b2-ijms-14-09686]\] including 70 genes, the "recurrence-score" developed by Paik *et al.* \[[@b9-ijms-14-09686]\] including 21 genes, the "two-gene-ratio model" \[[@b12-ijms-14-09686]\] including 2 genes and the "Insulin Resistance" signature including 15 genes \[[@b20-ijms-14-09686]\] ([Table 1](#t1-ijms-14-09686){ref-type="table"}). Since some genes are present in more than one signature, the final extracted set was made up of 98 genes (194 Affy-probes) ([Table 1](#t1-ijms-14-09686){ref-type="table"}).

2.2. Gene Selection on the Merged GEO Datasets
----------------------------------------------

The 98 genes selected from the published signatures were first tested in univariate analysis for their association with disease free survival (DFS). Forty-eight genes resulted associated with DFS with a *p* value \< 0.01 and were selected for the subsequent step. Using an unsupervised hierarchical clustering algorithm, 20 clusters were selected grouping genes with similar expression profiles. A gene was selected within each cluster using a multivariate Cox model, choosing the one most associated with DFS: the final 20-genes set, all highly associated with DFS, are reported in [Table 2](#t2-ijms-14-09686){ref-type="table"}.

2.3. Tumor Samples
------------------

Among 350 consecutive invasive breast cancer patients with full information about tumor, adjuvant treatments, follow up, relapse, death and causes of death, treated between 1998 and 2001, 89 cases (25.4%) were removed from the study because of the low RNA concentration (below 10 ng/μL) or high degradation (*Ct* values for *ACTB* and *B2M* over 34). The remaining 261 cases were split in two biological sample datasets: The training (137 cases) and the validation set (124 cases) by a simple criteria of consecutiveness.

The clinical and demographic characteristics of the patients included in the training and in the validation set are summarized in [Table 3](#t3-ijms-14-09686){ref-type="table"} and reported in detail in the supplementary file. Due to a simple criteria of consecutiveness building the sets, the Training set has a longer mean follow up (100.7 months; range 59--123) as compared with the Validation set (89.2; 61--121). Nevertheless, the only significant differences between the two sets was the use of anthracycline-based regimens in the adjuvant setting (Training 16% *vs.* Validation 32.2%; *p* = 0.01) and an higher incidence of G3 tumors in the Validation Set (30.6% *vs.* 19.7, *p* = 0.04). The lack of information about HER2 Status is related to the temporal context of the selected cases (1998--2001) and it was evaluated "*a posteriori*" just in 40% of relapsed patients. Any other clinical and biological pattern is similar and reflecting the "real life" picture of the disease in North East of Italy at this time.

2.4. Signature Definition on the Training Set
---------------------------------------------

A multivariate stepwise Cox analysis was run on the breast cancer samples including the 20 selected genes. The Cox model selected a final set of five genes independently associated with DFS ([Table 4](#t4-ijms-14-09686){ref-type="table"}): *FGF18* (HR = 1.13, *p* = 0.05), *BCL2* (HR = 0.57, *p* = 0.001), *PRC1* (HR = 1.51, *p* = 0.001), *MMP9* (HR = 1.11, *p* = 0.08), *SERF1a* (HR = 0.83, *p* = 0.007).

These five genes were combined into a linear score (signature) weighted according to the coefficients of the Cox model ([Table 4](#t4-ijms-14-09686){ref-type="table"}), as:
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This score ranged from −2.95 to 2.91, with a mean value of −0.48 a SD of 1.00. The linear score was highly associated with DFS in the training set: HR = 2.7, 95% CI = 1.9--4.0, *p* \< 0.001.

The score was then categorized in three groups according to the tertiles of its distribution. The DFS according to the three risk groups is reported in [Figure 2](#f2-ijms-14-09686){ref-type="fig"}: Patients with an intermediate risk signature had an HR = 6.03, (95% CI = 1.35--27.0, *p* = 0.019) and patients with a high risk signature had an HR = 10.8, (95% CI = 2.51--46.64, *p* = 0.001) as compared to patients with a low risk signature.

2.5. Signature Evaluation on the Validation Set
-----------------------------------------------

The signature defined on the training set was evaluated on the independent set of data of the 124 patients included in the validation set. The discrimination ability of the signature was assessed on the validation set by a Kaplan Meier analysis, using the same cut offs classifying patients at low, intermediate or high risk of disease relapse as defined on the training set.

The score resulted highly associated with DFS also in the validation set (*p* \< 0.001) ([Figure 3](#f3-ijms-14-09686){ref-type="fig"}). Patients with an "intermediate risk" signature had an HR = 2.1 (95% CI = 0.72--6.2, *p* = 0.17) and patients with a high risk signature had an HR = 5.4 (95% CI = 2.0--14.4, *p* = 0.001) as compared to patients with a low risk signature.

2.6. Inter and Intra Assay Reproducibility
------------------------------------------

Three serial sections from three cases each were evaluated independently in triplicate calculating the coefficients of variation (CVs) for the Recurrent Score in the same run and in different runs. The intra-assay and the inter-assay CVs was 3.7% and 4.7%, respectively.

2.7. Univariate Analysis
------------------------

In the Univariate Analysis variables significantly related to DFS were Nodal Status (*p* = 0.0000001), T Size (*p* = 0.000002), the five gene Signature (*i* = 0.000043), Ki67 (*p* = 0.0007) and Grading (*p* = 0.027) ([Table 5](#t5-ijms-14-09686){ref-type="table"}).

2.8. Multivariate Analysis
--------------------------

The Multivariate Analysis (Cox Regression) indicates that Nodal Status (*p* = 0.00001), T Size (*p* = 0.0002) and the five-gene Signature (*p* = 0.0004) are significantly related to DFS, while Ki67 (cut off: 14%), Grading and Chemo- or Endocrine Adjuvant Treatments are not ([Table 6](#t6-ijms-14-09686){ref-type="table"}). The five-gene Signature HR is slightly affected by adjuvant treatments: [Table 7](#t7-ijms-14-09686){ref-type="table"} summarized data about the five-gene signature in presence or absence of Adjuvant treatment.

2.9. Discussion
---------------

In this study we developed a five-gene recurrence score able to estimate the likelihood of recurrence in a series of consecutive breast cancer tissue samples. These five informative genes were selected by a multistep approach summarized in [Figure 1](#f1-ijms-14-09686){ref-type="fig"}. Firstly, we identified *in silico* a subset of 20 mRNA differentially regulated in breast cancer analyzing several publicly available array gene expression data using R/Bioconductor package. We further evaluated, *in vitro*, the expression level of these 20 genes in 261 consecutive invasive breast cancer cases not selected for age, adjuvant treatment, nodal and estrogen receptor status from paraffin embedded sections. The only requested feature was a minimum follow up of 5 years with full clinical data. Each tissue block was reviewed by a pathologist to ensure greater than 70% content of tumor cells. The gene expression analysis was based on RTqPCR. The biological samples dataset was split into a training and a validation dataset. The gene signature was developed on the training set by a multivariate stepwise Cox analysis selecting five genes independently associated with DFS. These five genes were combined into a linear score (signature) weighted according to the coefficients of the Cox model. The signature was then evaluated on the validation set assessing the discrimination ability by a Kaplan Meier analysis, using the same cut offs classifying patients at low, intermediate or high risk of disease relapse as defined on the training set.

These five genes of interest were identified without any *a priori* selection for gene function or cancer involvement, but simply for the relationship between their expression level and DFS. Interestingly, except for *SERF1a* which the function is still unknown, they have been described to play an important role in cancer as follows:

1.  *FGF18*: Its over-expression in tumors has also been demonstrated \[[@b21-ijms-14-09686],[@b22-ijms-14-09686]\]. *FGF18* expression is up-regulated through the constitutive activation of the *Wnt* pathway observed in most colorectal carcinomas \[[@b23-ijms-14-09686]\]. As a secreted protein, FGF18 can thus affect both the tumor and the connective tissue cells of the tumor microenvironment.

2.  *BCL2*: Over-expression of BCL2 protein has been identified in a variety of solid organ malignancies, including breast cancer. *BCL2* transcript over-expression is related to unfavorable prognosis in Oncotype Dx \[[@b9-ijms-14-09686]\] and in Mammaprint® \[[@b3-ijms-14-09686]\].

3.  *PRC1*: It associates with the mitotic spindle and has been found to play a crucial role in the completion of cytokinesis \[[@b24-ijms-14-09686],[@b25-ijms-14-09686]\]. *PRC1* is negatively regulated by p53 and it is over-expressed in p53 defective cells \[[@b26-ijms-14-09686]\] suggesting that the gene is tightly regulated in a cancer-specific manner.

4.  *MMP9*: Metalloproteases are frequently up-regulated in the tumor microenvironment \[[@b27-ijms-14-09686]\]. *MMP9* influence many aspects of tissue function by cleaving a diverse range of extracellular matrix, cell adhesion, and cell surface receptors, and regulate the bioavailability of many growth factors and chemokines \[[@b28-ijms-14-09686]\].

5.  *SERF1a*: The function of *SERF1a* is not already known.

The biological properties of these genes are related with four of the six hallmarks of cancer proposed by Hanahan *et al.* \[[@b29-ijms-14-09686],[@b30-ijms-14-09686]\]: *FGF18* should be included in "Self-sufficiency in growth signal" group, *BCL2* in "Evading apoptosis" group, *PRC1* in "Limitless replication potential" group, *MMP9* in "Tissue invasion and metastasis" group, while the function of *SERF1a* is still unknown. These findings establish a link between our proposed molecular signature of breast cancer and the underlying capabilities acquired during the multistep development of human tumors previously categorized \[[@b29-ijms-14-09686],[@b30-ijms-14-09686]\].

For an experimental point of view, our assay appears affordable, not time consuming, it needs FFPE tissue and it might be performed easily in almost all laboratories with the required RT-qPCR instrumentations. Importantly it was validated on a "real life" clinical setting with a set of consecutive breast cancer cases irrespectively from age, nodal and estrogen receptor status, adjuvant treatment with at least a minimum follow up of 5 years. An important limit of our approach was that the test was possible in 74.6% of the initial set of cases due to RNA degradation from FFPE tissues according to the literature regarding other signatures \[[@b19-ijms-14-09686],[@b31-ijms-14-09686],[@b32-ijms-14-09686]\]. RNA degradation can be monitored simply evaluating the Ct values of the housekeeping genes used for normalization. Multicentric studies will be needed to evaluate possible pitfalls due to experimental inter-laboratory variability and above all increasing the reliability of the assay. A further step will be the analysis of the predictive value of the five-gene signature in ER positive population of tamoxifen alone benefit and of chemotherapy added to tamoxifen.

3. Experimental Section
=======================

3.1. Tumor Samples Enrolled in This Study
-----------------------------------------

Tumor samples were obtained from routinely processed formalin-fixed, paraffin embedded sections retrieved from 350 consecutive invasive breast cancer patients with full information about tumor, adjuvant treatments, follow up, relapse, death and causes of death, treated between 1998 and 2001. In order to test our signature in a "real life" clinical setting, we decided to use consecutive non metastatic breast cancer cases irrespectively from age, nodal and estrogen receptor status, adjuvant treatment. The only requested pattern was a minimum follow up of 5 years with full clinical data. All patient information was handled in accordance with review board approved protocols and in compliance with the Helsinki declaration \[[@b33-ijms-14-09686]\]. Hematoxylin and Eosin (H & E) sections were reviewed to identify paraffin blocks with tumor areas. Histological type and grade were assessed according to the World Health Organization criteria \[[@b34-ijms-14-09686]\]. The detailed histological and clinical feature of each patient enrolled in this study is available in the supplementary information file. Paraffin blocks corresponding to histology sections that showed the highest relative amount of tumor *vs.* stroma, few infiltrating lymphoid cells and that lacked significant areas of necrosis were selected. Three 20 μm thick sections were cut, followed by one H & E control slide. The tumor area selected for the analysis was marked on this control slide to ensure greater than 70% content of neoplastic cells. Tumor areas dissected ranged from 0.5 to 1.0 cm^2^ wide.

3.2. Ethics Statement
---------------------

The use of tissues for this study has been approved by the Ethics Committee of Centro Oncologico, ASS1 triestina & Università di Trieste, Italy. A comprehensive written informed consent was signed for the surgical treatment that produced the tissue samples and the related diagnostic procedures. All information regarding the human material used in this study was managed using anonymous numerical codes, clinical data were not used and samples were handled in compliance with the Helsinki declaration (<http://www.wma.net/en/30publications/10policies/b3/>).

3.3. Gene Expression Analysis on Breast Cancer Samples
------------------------------------------------------

### 3.3.1. RNA Isolation

Paraffin-embedded tumor material obtained from the 20 μm thick sections was de-paraffinized in xilene at 50 °C for 3 min and rinsed twice in absolute ethanol at room temperature. Total RNA was extracted using the RecoverAll kit (Ambion, Austin, TX, USA), including a DNase step according to the manufacturer's recommended protocol. RNA concentration was measured by Quant-iT™ RNA kit (Invitrogen, Carlsbad, CA, USA).

### 3.3.2. Primers Design

Primers were designed using Primer3 software (<http://simgene.com/Primer3>) and are described in [Table 8](#t8-ijms-14-09686){ref-type="table"}. Amplicons were tested by *MFOLD* (<http://mfold.rna.albany.edu/?q=mfold>) in order to avoid secondary structures within primer positions and they were tested by repeatmasker (<http://www.repeatmasker.org>) and primer-BLAST (<http://www.ncbi.nlm.nih.gov/tools/primer-blast>) for primer specificity.

### 3.3.3. Two Step RTqPCR Analysis

Fourteen μL of total RNA was subjected to reverse transcription using SuperScript® VILO™ cDNA Synthesis kit (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's recommended protocol. One microlitres of cDNA was amplified in duplicate adding 10 picomoles of each primer (see [Table 8](#t8-ijms-14-09686){ref-type="table"} for sequence details) to the 1x QuantiFast™ SYBR® Green PCR solution (Qiagen, Hilden, Germany) in a final volume of 25 μL.

Cycling conditions consisted of 5 min at 95 °C, 10 s at 95 °C, 30 s at 60 °C for a total of 40 cycles, using Stratagene Mx3000™ or ABI SDS 7000™ instruments. Plate reading was performed during the 60 °C step.

For each primer set, standard curves made from serial dilutions of cDNA from MCF7 cell lines (see [Table 2](#t2-ijms-14-09686){ref-type="table"}) were used to estimate PCR reaction efficiency (E) using the formula: E (%) = (10^\[−1/slope\]^ − 1) × 100. The expression levels of each of the 20 genes selected were normalized by *GeNorm* \[[@b35-ijms-14-09686]\] using 2 housekeeping genes (*B2M* e *ACTB*) and the relative quantification was calculated by the statistical computing language *R*. The human breast cancer cell line MCF7 was purchased from American Type Culture Collection (ATCC HTB22; derived from a human breast adenocarcinoma). Cells were maintained in minimal essential medium (MEM) (Invitrogen/Life technologies, Villebon-sur-Yvette, France) supplemented with 2 mM [l]{.smallcaps}-glutamine, 1.5 g/L sodium bicarbonate, 0.1 mM nonessential aa, 1 mM pyruvate sodium, 0.01 mg/mL bovine insulin, and 10% fetal bovine serum (Thermo Scientific, Waltham, MA, USA) at 37 °C in a humidified atmosphere of 5% CO~2~.

3.4. Training and Validation Dataset
------------------------------------

The biological samples dataset was split into the training and the validation dataset. The training set consists of the first 144 consecutive cases and the validation of the last 127 cases. The gene signature was developed on the training set. Once the signature has been fully specified, the validation set was accessed once and only for estimating the prediction accuracy of the signature. A multivariate stepwise Cox analysis was run on the breast cancer training set samples including the 20 selected genes. The stepwise procedure was run to select genes independently associated with DFS (*p* for inclusion \<0.10). The overall workflow shown in [Figure 1](#f1-ijms-14-09686){ref-type="fig"} summarizes every step starting from selection of markers from the literature since the validation of the gene signature. Reproducibility within and between blocks was assessed by performing the test in serial sections from three blocks representing three cases. We finally performed a multivariate Cox proportional-hazards analysis in a model that included treatment received (no adjuvant therapy *vs.* chemotherapy, hormonal therapy, or both) and the final gene Signature (both Training and Validation sets included), using the NCSS 2001 Statistical software (NCSS Inc., Kaysville, UT, USA, 2001).

3.5. Univariate and Multivariate Analysis
-----------------------------------------

We performed a univariate analysis including Age, T size, Nodal status, Grading, Ki67, adjuvant treatments and the 5-gene signature, followed by a multivariate Cox proportional-hazards analysis in a model that included treatment received (no adjuvant therapy *vs.* chemotherapy, hormonal therapy, or both) and the 5-gene Signature (Low/Intermediate/High Risk; both Training and Validation sets included), using the NCSS 2001 Statistical software (NCSS Inc., Kaysville, UT, USA, 2001).

4. Conclusions
==============

We developed a prognostic tool for early breast cancer based on the analysis of the relative expression level of *FGF18*, *BCL2*, *PRC1*, *MMP9* and *SERF1A* in combination. Our signature has a good discriminating ability when tested on the validation set. We suppose that, after a necessary further clinical validation on a higher number of cases, it could be proposed as non expensive prognostic signature for disease free survival in breast cancer patients where the indication for adjuvant chemotherapy added to endocrine treatment is uncertain.
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![Training set: Probability of 5 years relapse: Disease free survival (DFS) according to the risk groups defined by the gene signature in the training set: Low risk group (blue curve), intermediate risk group (green curve), high risk group (red curve). The hazard ratio (HR) of DFS for intermediate risk patients as compared to low risk is 6.0 (95% Confidence Intervals (CI) = 1.35--27.0, *p* = 0.019 and the HR of DFS for high risk patients as compared to low risk is 10.8 (95% CI = 2.51--46.6, *p* = 0.001).](ijms-14-09686f2){#f2-ijms-14-09686}

![Validation set: Probability of 5 years relapse. Disease free survival (DFS) according to the risk groups defined by the gene signature in the validation set: low risk group (blue curve), intermediate risk group (green curve), high risk group (red curve). The hazard ratio (HR) of DFS for intermediate risk patients as compared to low risk is 2.1 (95% Confidence Intervals (CI) = 0.72--6.2, *p* = 0.17) and the HR of DFS for high risk patients as compared to low risk is 5.4 (95% CI = 2.0--14.4, *p* = 0.001).](ijms-14-09686f3){#f3-ijms-14-09686}

###### 

Genes selected and also present in other previously published signatures (1 = van't Veer *et al.* \[[@b2-ijms-14-09686]\], 2 = Paik *et al.* \[[@b9-ijms-14-09686]\], 3 = Gennari *et al.* \[[@b20-ijms-14-09686]\], 4 = 2 Ma *et al.* \[[@b12-ijms-14-09686]\], 1.5 = van't Veer *et al.* \[[@b2-ijms-14-09686]\] with Paik *et al.* \[[@b9-ijms-14-09686]\]).

  Symbol     AffyID         Group   Affychip   Symbol        AffyID         Group   Affychip   Symbol        AffyID         Group   Affychip
  ---------- -------------- ------- ---------- ------------- -------------- ------- ---------- ------------- -------------- ------- ----------
  ALDH4A1    203722_at      1.00    A          MKI67         212021_s\_at   2.00    A          MCM6          201930_at      1.00    A
  AP2B1      200612_s\_at   1.00    A          MKI67         212022_s\_at   2.00    A          MELK          204825_at      1.00    A
  AP2B1      200615_s\_at   1.00    A          MKI67         212023_s\_at   2.00    A          MKI67         212020_s\_at   2.00    A
  AURKA      204092_s\_at   2.00    A          MMP11         203876_s\_at   2.00    A          SLC2A3        240055_at      1.00    
  AURKA      208079_s\_at   2.00    A          MMP11         203878_s\_at   2.00    A          ZNF533        229019_at      1.00    
  AURKA      208080_at      2.00    A          MMP9          203936_s\_at   1.00    A          ZNF533        243929_at      1.00    
  AYTL2      201818_at      1.00    A          MYBL2         201710_at      2.00    A          IGF1          209540_at      3.00    A
  BAG1       202387_at      2.00    A          NDC80         204162_at      1.00    A          IGF1R         203628_at      3.00    A
  BAG1       211475_s\_at   2.00    A          NUSAP1        218039_at      1.00    A          IGF2          202410_x\_at   3.00    A
  BBC3       211692_s\_at   1.00    A          ORC6L         219105_x\_at   1.00    A          IGFBP4        201508_at      3.00    A
  BC045642   212248_at      1.00    A          OXCT1         202780_at      1.00    A          IGFBP5        203424_s\_at   1.00    A
  BC045642   212250_at      1.00    A          PALM2-AKAP2   202759_s\_at   1.00    A          IGFBP5        203425_s\_at   1.00    A
  BC045642   212251_at      1.00    A          PALM2-AKAP2   202760_s\_at   1.00    A          IGFBP5        203426_s\_at   1.00    A
  BCL2       203684_s\_at   2.00    A          PECI          218025_s\_at   1.00    A          IGFBP5        211958_at      1.00    A
  BCL2       203685_at      2.00    A          PGR           208305_at      2.00    A          IGFBP5        211959_at      1.00    A
  BCL2       207004_at      2.00    A          PITRM1        205273_s\_at   1.00    A          IGFBP6        203851_at      3.00    A
  BCL2       207005_s\_at   2.00    A          PQLC2         220453_at      1.00    A          IGFBP7        201163_s\_at   3.00    A
  BF034907   206023_at      1.00    A          PRC1          218009_s\_at   1.00    A          IL17RB        219255_x\_at   4.00    A
  BIRC5      202094_at      2.00    A          RAB6A         201045_s\_at   1.00    A          IL6ST         204863_s\_at   3.00    A
  BIRC5      202095_s\_at   2.00    A          RAB6A         201047_x\_at   1.00    A          INSIG1        201627_s\_at   3.00    A
  BIRC5      210334_x\_at   2.00    A          RAB6A         201048_x\_at   1.00    A          IRS1          204686_at      3.00    A
  C16orf61   218447_at      1.00    A          RAB6A         210406_s\_at   1.00    A          IRS2          209184_s\_at   3.00    A
  C20orf46   219958_at      1.00    A          RFC4          204023_at      1.00    A          LGP2          219364_at      1.00    A
  C9orf30    205122_at      1.00    A          SCUBE2        219197_s\_at   1.50    A          LOC643008     229740_at      1.00    B
  C9orf30    205123_s\_at   1.00    A          SERF1A        219982_s\_at   1.00    A          MCM6          238977_at      1.00    B
  CCNB1      214710_s\_at   2.00    A          SLC2A3        202497_x\_at   1.00    A          MS4A7         223343_at      1.00    B
  CCNE2      205034_at      1.00    A          SLC2A3        202498_s\_at   1.00    A          MS4A7         223344_s\_at   1.00    B
  CCNE2      211814_s\_at   1.00    A          SLC2A3        202499_s\_at   1.00    A          MS4A7         224358_s\_at   1.00    B
  CD68       203507_at      2.00    A          SLC2A3        216236_s\_at   1.00    A          PALM2-AKAP2   226694_at      1.00    B
  CDC42BPA   214464_at      1.00    A          SLC2A3        222088_s\_at   1.00    A          QSOX2         227146_at      1.00    B
  CENPA      204962_s\_at   1.00    A          STK32B        219686_at      1.00    A          QSOX2         235239_at      1.00    B
  CENPA      210821_x\_at   1.00    A          TGFB3         209747_at      1.00    A          RTN4RL1       229097_at      1.00    B
  COL4A2     211964_at      1.00    A          TNFRSF10B     209295_at      3.00    A          RTN4RL1       232596_at      1.00    B
  COL4A2     211966_at      1.00    A          TNFRSF12A     218368_s\_at   3.00    A          RTN4RL1       242102_at      1.00    B
  CTSL2      210074_at      2.00    A          TNFRSF21      214581_x\_at   3.00    A          RUNDC1        226298_at      1.00    B
  DCK        203302_at      1.00    A          TNFSF10       214329_x\_at   3.00    A          RUNDC1        235040_at      1.00    B
  DIAPH3     220997_s\_at   1.00    A          TSPYL5        213122_at      1.00    A          SERF1A        223538_at      1.00    B
  DTL        218585_s\_at   1.00    A          UCHL5         219960_s\_at   1.00    A          SERF1A        223539_s\_at   1.00    B
  ECT2       219787_s\_at   1.00    A          WISP1         206796_at      1.00    A          SLC2A3        236180_at      1.00    B
  EGLN1      221497_x\_at   1.00    A          WISP1         211312_s\_at   1.00    A          SLC2A3        236571_at      1.00    B
  ESM1       208394_x\_at   1.00    A          AA834945      230365_at      1.00    B          GRB7          210761_s\_at   2.00    A
  ESR1       205225_at      2.00    A          AA834945      235039_x\_at   1.00    B          GSTM1         204418_x\_at   2.00    A
  ESR1       207672_at      2.00    A          AI224578      235247_at      1.00    B          GSTM1         204550_x\_at   2.00    A
  ESR1       211233_x\_at   2.00    A          AI283268      232579_at      1.00    B          GSTM1         215333_x\_at   2.00    A
  ESR1       211234_x\_at   2.00    A          AP2B1         234064_at      1.00    B          GSTM3         202554_s\_at   1.00    A
  ESR1       211235_s\_at   2.00    A          AW014921      230710_at      1.00    B          HER2          210930_s\_at   2.00    A
  ESR1       211627_x\_at   2.00    A          AW014921      236480_at      1.00    B          HER2          216836_s\_at   2.00    A
  ESR1       215552_s\_at   2.00    A          AYTL2         241511_at      1.00    B          HOXB13        209844_at      4.00    A
  ESR1       217163_at      2.00    A          CDCA7         224428_s\_at   1.00    B          HRASLS        219983_at      1.00    A
  ESR1       217190_x\_at   2.00    A          CDCA7         230060_at      1.00    B          HRASLS        219984_s\_at   1.00    A
  EXT1       201995_at      1.00    A          COL4A2        237624_at      1.00    B          IDE           203328_x\_at   3.00    A
  EXT1       215206_at      1.00    A          DCK           224115_at      1.00    B          FBXO31        223745_at      1.00    B
  FBXO31     219784_at      1.00    A          DTL           222680_s\_at   1.00    B          FBXO31        224162_s\_at   1.00    B
  FBXO31     219785_s\_at   1.00    A          EBF4          233032_x\_at   1.00    B          FBXO31        236873_at      1.00    B
  FBXO31     222352_at      1.00    A          EBF4          233850_s\_at   1.00    B          FGF18         231382_at      1.00    B
  FGF18      206986_at      1.00    A          ECT2          234992_x\_at   1.00    B          FLT1          226497_s\_at   1.00    B
  FGF18      206987_x\_at   1.00    A          ECT2          237241_at      1.00    B          FLT1          226498_at      1.00    B
  FGF18      211029_x\_at   1.00    A          EGLN1         223045_at      1.00    B          FLT1          232809_s\_at   1.00    B
  FGF18      211485_s\_at   1.00    A          EGLN1         223046_at      1.00    B          GPR180        231871_at      1.00    B
  FGF18      214284_s\_at   1.00    A          EGLN1         224314_s\_at   1.00    B          GPR180        232912_at      1.00    B
  FLT1       204406_at      1.00    A          EXT1          232174_at      1.00    B          GSTM3         235867_at      1.00    B
  FLT1       210287_s\_at   1.00    A          EXT1          234634_at      1.00    B          LOC286052     241370_at      1.00    B
  FLT1       222033_s\_at   1.00    A          EXT1          237310_at      1.00    B                                               
  GMPS       214431_at      1.00    A          EXT1          239227_at      1.00    B                                               
  GNAZ       204993_at      1.00    A          EXT1          239414_at      1.00    B                                               
  GPR126     213094_at      1.00    A          EXT1          242126_at      1.00    B                                               

###### 

Final 20 genes set, all highly associated with Disease free survival (DFS).

  Index   Symbol    Cluster   AffyID         Group   Chip   logHR   HR     *p* value
  ------- --------- --------- -------------- ------- ------ ------- ------ -----------
  114     PRC1      1         218009_s\_at   1       A      0.26    1.29   \<0.00001
  120     ORC6L     16        219105_x\_at   1       A      0.36    1.44   0.000201
  38      MMP9      14        203936_s\_at   1       A      0.14    1.15   0.000607
  11      AYTL2     5         201818_at      1       A      0.38    1.46   0.000828
  69      TGFB3     3         209747_at      1       A      −0.23   0.79   0.000860
  145     SERF1A    19        223539_s\_at   1       B      0.36    1.44   0.001192
  163     FGF18     8         231382_at      1       B      −0.41   0.67   0.003375
  156     QSOX2     18        227146_at      1       B      0.51    1.66   0.003409
  143     MS4A7     15        223344_s\_at   1       B      −0.16   0.85   0.004351
  126     FBXO31    7         219785_s\_at   1       A      0.31    1.36   0.004459
  164     GPR180    9         231871_at      1       B      0.33    1.39   0.005603
  54      PITRM1    17        205273_s\_at   1       A      0.26    1.30   0.007143
  33      BCL2      6         203685_at      2       A      −0.16   0.85   0.003310
  68      IGF1      2         209540_at      3       A      −0.22   0.80   0.000001
  35      IGFBP6    2         203851_at      3       A      −0.40   0,67   0.000002
  47      IL6ST     12        204863_s\_at   3       A      −0.19   0.83   0.000028
  45      IRS1      13        204686_at      3       A      −0.19   0.82   0.001258
  7       IGFBP7    4         201163_s\_at   3       A      −0.41   0.66   0.001529
  102     TNFSF10   20        214329_x\_at   3       A      −0.20   0.82   0.004448
  26      IDE       11        203328_x\_at   3       A      0.52    1.68   0.005188

###### 

Characteristics of patients and tumors in the Training and Validation sets.

                                Training Set      Validation Set   *p* value           
  ----------------------------- ----------------- ---------------- ----------- ------- ----------------------------------------------------------
  **Nr of Patients**            137               124              ns                  
  **Mean Age (range)**          62.3 (35--87)     61.1 (33--87)    ns                  
  **Mean Follow up (months)**   100.7 (59--123)   89.2 (61--121)   ns                  
  **Histology**                 ***n***           **%**            ***n***     **%**   ***p*value**
  Ductal                        86                62.8             83          66.9    ns
  Lobular                       26                19               16          12.9    ns
  Tubular-Lobular               12                8.8              10          8.5     ns
  Medullary/Apocrine            2                 1.4              3           2.4     ns
  Other                         11                8.02             12          9.6     ns
                                                                                       
  **T Size**                                                                           
  T1                            78                56.9             82          66.1    ns
  T2                            53                38.7             37          29.8    ns
  T3                            3                 2.2              3           2.4     ns
  Tx                            3                 2.2              2           1.6     ns
                                                                                       
  **N Status**                                                                         
  pN0                           89                65               75          60.5    ns
  pN1a                          26                19               26          21      ns
  pN+ 4--10                     11                8.1              7           5.6     ns
  pN+ \>10                      10                7.3              14          11.3    ns
  NX                            0                                                      
  ER/PgR pos                    123               85.4             97          76.38   ns
  HER2 NA                       125               91.2             79          73.7    *p* = 0.05[\*](#tfn1-ijms-14-09686){ref-type="table-fn"}
                                                                                       
  **Grading**                                                                          
  G1                            33                24.1             20          16.1    ns
  G2                            51                37.2             57          46      ns
  G3                            27                19.7             38          30.6    *p* = 0.04
  G NA                          26                19               9           7.3     ns
                                                                                       
  **Ki67**                                                                             
  High (\>14%)                  60                43.8             60          48.4    Ns
  Low (\<15%)                   77                56.2             60          48.4    ns
  Adjuvant Chemo                49                35.8             57          46      ns
  Anthracycline-based           22                16               40          32.2    *p* = 0.01
  Adjuvant endocrine (any)      110               80.3             96          77.4    *p* = 0.01
  Relapses                      33                24               38          30.6    ns
  Mean DFS, months              51.4                               47.2                ns
  Deaths                        33                24               39          31.4    ns

In the Validation Set HER2 status was evaluated in relapsed patients.

###### 

Genes selected in the five-genes signature. Variables in the Equation.

                                                              95.0% CI for Exp(B)   
  ---------- -------- ------- --------- ---- ------- -------- --------------------- -------
                                                                                    
  gene       B        SE      Wald      df   Sig.    Exp(B)   Lower                 Upper
  *FGF18*    0.125    0.064   3.736     1    0.053   1.133    0.998                 1.285
  *BCL2*     −0.56    0.173   10.4444   1    0.001   0.571    0.407                 0.802
  *PRC1*     0.409    0.12    11.712    1    0.001   1.506    1.191                 1.903
  *MMP9*     0.104    0.06    3.031     1    0.082   1.109    0.987                 1.247
  *SERF1A*   −0.188   0.069   7.375     1    0.007   0.828    0.723                 0.949

###### 

Univariate analysis.

  Variable                                   Regression coefficient (B)   SE      Exp (B)   Mean     Z-value   Probability level
  ------------------------------------------ ---------------------------- ------- --------- -------- --------- -------------------
  Nodal Status (pN0/pN1a/pN2)                0.591                        0.100   1.806     0.062    5.1       0.0000001
  T Size (pT1/pT2/pT3)                       3.647                        7.639   1.037     20.195   4.77      0.000002
  5 gene Signature (High/Intermediate/Low)   0.646                        0.158   1.909     1.984    4.09      0.000043
  Ki67 (High/Low)                            0.427                        0.126   1.533     1.933    3.38      0.0007
  Grading (G1/G2/G3)                         0.298                        0.135   1.348     1.798    2.2       0.027

###### 

Multivariate Cox regression analysis.

  Variable                                   Regression coefficient (B) (95% CI)   SE      Exp (B)   Mean     Z-value   Probability level
  ------------------------------------------ ------------------------------------- ------- --------- -------- --------- -------------------
  Nodal Status (pN0/pN1a/pN2)                0.551 (0.350--0.752)                  0.102   1.736     0.655    5.379     0.00001
  T Size (pT1/pT2/pT3)                       0.562 (0.269--0.854)                  0.149   1.754     1.449    3.762     0.0002
  5 gene Signature (High/Intermediate/Low)   0.666 (0.298--1.034)                  0.187   1.947     1.9767   3.549     0.0004
  Ki67 (High/Low)                            0.27 (−0.028--0.569)                  0.152   1.31      1.748    1.77      0.076
  Grading (G1/G2/G3)                         −0.111 (−0.387--0.164)                0.14    0.894     1.798    −0.792    0.428
  AdjChemo (Yes/No)                          0.061 (−0.479--0.601)                 0.275   1.063     1.604    0.221     0.824
  Adj Endocrine (Yes/No)                     0.032 (−0.556--0.622)                 0.3     1.033     1.209    0.109     0.912

###### 

Hazard Ratio Longrank (Cox-Mantel) for five-gene signature in presence or absence of adjuvant treatments.

  Chemo or endocrine adjuvant treatment                                                       
  --------------------------------------- ------ ------------ ----------- ------ ------------ -----------
                                                                                              
                                          YES    NO                                           
  5 Gene Score                            HR     95% CI       *p* value   HR     95% CI       *p* value
  Low *vs*. High                          0.35   0.20--0.60   0.0006      0.16   0.08--0.32   0.0001
  Low *vs*. Intermediate                  0.98   0.45--2.11   0.9         0.29   0.11--0.77   0.0224
  Intermediate *vs*. High                 0.4    0.23--0.69   0.002       0.56   0.29--1.06   0.089

###### 

Primer sequences, slope, PCR efficiency and RSq of each of the 20 genes + 2 housekeeping genes.

              Primer forward            Primer reverse             Slope    Efficiency   RSq
  ----------- ------------------------- -------------------------- -------- ------------ -------
  B2M         ATGAGTATGCCTGCCGTGTGA     GGCATCTTCAAACCTCCATG       −3.051   112.7%       0.992
  ACTB        TTGCCGACAGGATGCAGAAGGA    AGGTGGACAGCGAGGCCAGGAT     −3.116   109.4%       0.998
  FBX031      GAGGACATCTTCCACGAGCAC     AGGTAGATGCGGCGGTAGGT       −3.293   101.2%       0.995
  FGF18       GGTAGTCAAGTCCGGATCAAGG    TCCAGAACCTTCTCGATGAACA     −3.217   104.6%       0.952
  BCL2        AGTACCTGAACCGGCACCTG      CAGAGACAGCCAGGAGAAATCA     −3.787   83.7%        0.999
  IGFBP7      ATGAAGTAACTGGCTGGGTGCT    TGAAGCCTGTCCTTGGGAAT       −3.043   113.1%       0.997
  IDE         AGCCCTTCTCCATGGAAACATA    CAGCTGACTTGGAAGGAGAGGT     −3.149   107.8%       0.998
  AYTL2       GTTGCCCTGTCTGTCGTCTG      CTTGAGGATGCAGGACAGGT       −3.057   112.4%       0.989
  ORC6L       TGAAGTGCCCCTTGGACAG       CAGGCCCAGTAAACACTCAAAAG    −3.093   110.5%       0.996
  MS4A7       CCCTCAAAGAGAGAAACCTGGA    ATCAACAGGCAACACAGGATCT     −3.162   107.1%       0.964
  OSOX2       CGTGTTCTCTCTGGAAACTGTTC   GAACGTACCTCCTCATTGTCTGC    −3.236   103.7%       0.998
  PITRM1      GGAAAATTCACACAGCAAGACA    AGAGGCCGTACAAGAAGTGGT      −3.192   105.7%       0.997
  TGFb3       AACTTCTGCTCAGGCCCTTG      AGGCAGATGCTTCAGGGTTC       −3.216   104.6%       0.998
  PRC-1-201   CCGTGTCTCGACTTCCTCCT      CGTTGAGCTCCAGGTTCTCC       −3.092   110.6%       0.991
  GPR180      GATTCTACGCCTGCATCCACT     CCCTGCTAAGTTGTGGTGTGAA     −3.076   111.4%       0.996
  MMP9        GCAAGCTGGACTCGGTCTT       CCTGTGTACACCCACACCTG       −2.198   185.1%       0.953
  IGFBP6      GAATCCAGGCACCTCTACCAC     AGTCCAGATGTCTACGGCATGG     −2.821   126.2%       0.998
  IRS1        CAGTTTCCAGAAGCAGCCAGAG    GAGGATTTGCTGAGGTCATTTA     −3.136   108.4%       0.990
  IL6ST210    CAGTGGTCACCTCACACTCCTC    TTTGTCATTTGCTTCTATTTCCA    −3.071   111.7%       0.972
  IGF1        TATCAGCCCCCATCTACCAAC     TCTTGTTTCCTGCACTCCCTCT     −3.012   102.3%       0.998
  TNSF        TCCTCAGAGAGTAGCAGCTCACA   CCTTGATGATTCCCAGGAGTT      −2.628   140.2%       0.759
  SERF1A      CCAGGAAATTAGCAAGGGAAAG    CTTGTCTGCATAGACTTCTTCTCA   −2.927   119.6%       0.974
